These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19422100)

  • 1. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Kruhlak NL; Benz RD; Aragonés Sabaté D; Marchant CA; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):43-65. PubMed ID: 19422100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Ursem CJ; Kruhlak NL; Benz RD; Sabaté DA; Yang C; Klopman G; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):23-42. PubMed ID: 19422098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.
    Ursem CJ; Kruhlak NL; Contrera JF; MacLaughlin PM; Benz RD; Matthews EJ
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):1-22. PubMed ID: 19422096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
    Matthews EJ; Frid AA
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
    Frid AA; Matthews EJ
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):276-89. PubMed ID: 19941924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data.
    Zhu X; Kruhlak NL
    Toxicology; 2014 Jul; 321():62-72. PubMed ID: 24721472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Matthews EJ; Kruhlak NL; Weaver JL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Dec; 1(4):243-54. PubMed ID: 16472241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adverse Event Trends Associated with Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event Report Database].
    Sasaoka S; Hatahira H; Hasegawa S; Motooka Y; Fukuda A; Naganuma M; Umetsu R; Nakao S; Shimauchi A; Ueda N; Hirade K; Iguchi K; Nakamura M
    Yakugaku Zasshi; 2018; 138(1):123-134. PubMed ID: 29311458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method.
    Rodgers AD; Zhu H; Fourches D; Rusyn I; Tropsha A
    Chem Res Toxicol; 2010 Apr; 23(4):724-32. PubMed ID: 20192250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA-approved drug labeling for the study of drug-induced liver injury.
    Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
    Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.
    Matthews EJ; Kruhlak NL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Jan; 1(1):61-76. PubMed ID: 16472220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced liver injury following positive drug rechallenge.
    Papay JI; Clines D; Rafi R; Yuen N; Britt SD; Walsh JS; Hunt CM
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):84-90. PubMed ID: 19303041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.